Worth reading
61In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-85.9
Year-on-year change in operating income (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 January 2026 to 31 March 2026ConsolidatedJapanese GAAPNet Sales5,039¥ millionYear on year -24.9%Progress 22.1%
Operating profit216¥ millionYear on year -85.9%Progress 6.5%
Ordinary income388¥ millionYear on year -77.2%Progress 9.9%
Net income attributable to owners of the parent155¥ millionYear on year -86.4%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥2.24
Financial position at period-end
Total assets26,313¥ million
of which net assets 19,178 ¥ millionEquity ratio 72.5%vs. prior year-end -1.4pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenuePharmacy Systems Business ¥4,074 million (YoY -25.8%), Medical Systems Business ¥592 million (YoY -28.8%), Nursing Care and Welfare Systems Business ¥133 million (YoY +4.2%), Other Businesses ¥279 million (YoY -6.2%)
Segment profitPharmacy Systems Business ¥374 million (YoY -74.4%), Medical Systems Business ¥-170 million, Nursing Care and Welfare Systems Business ¥-76 million, Other Businesses ¥40 million (YoY +76.4%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥22,762 million (YoY -3.8%)
Operating profit¥3,316 million (YoY -9.8%)
Ordinary income¥3,939 million (YoY -8.7%)
Profit attributable to owners of the parent¥2,193 million (YoY -10.6%)
Revision to Earnings ForecastNot disclosed → Second quarter (cumulative) Net Sales ¥10,273 million (YoY -15.4%) / Operating profit ¥447 million (YoY -78.5%) / Ordinary income ¥791 million (YoY -67.0%) / Profit attributable to owners of parent for the quarter ¥344 million (YoY -78.5%)
Annual Dividend Forecast¥39 → ¥23（-41.0%）
Factors Behind Changes in Business Performance
The concentrated demand for the introduction of online eligibility verification systems and electronic prescriptions had run its course, resulting in a reactionary decline. In order to expand the future earnings base, the Company shifted its sales strategy, curbed efforts to promote replacements for existing customers, and allocated more sales resources to acquiring new customers from other companies and selling value-added products.
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 1 / Company name 株式会社コンダクト / Excluded Number of companies 0 / Company name Not disclosed
Impairment loss¥97 million
Breakdown of extraordinary income (loss)Extraordinary income Item Gain on sale of non-current assets / Amount Not disclosed / Extraordinary loss Item Loss on Disposal of Fixed Assets / Amount ¥4 million, Item Impairment Losses / Amount ¥97 million
Depreciation and amortization¥205 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable No / Subject person Not disclosed
Issued Shares at Period-End70,514,800
Treasury Shares at Period-End1,293,795
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026 to 31 March 2026 |
| Net Sales | ¥5,039 million (YoY -24.9%) |
| Operating profit | ¥216 million (YoY -85.9%) |
| Ordinary income | ¥388 million (YoY -77.2%) |
| Profit attributable to owners of the parent | ¥155 million (YoY -86.4%) |
| Net income per share | ¥2.24 |
| Equity ratio | End of the current fiscal period 72.5 / End of previous period 73.9 |
| Total assets | ¥26,313 million |
| Net assets | ¥19,178 million |
| Full-year earnings forecast | Net Sales ¥22,762 million (YoY -3.8%) / Operating profit ¥3,316 million (YoY -9.8%) / Ordinary income ¥3,939 million (YoY -8.7%) / Profit attributable to owners of the parent ¥2,193 million (YoY -10.6%) |
| Revision to Earnings Forecast | Not disclosed → Second quarter (cumulative) Net Sales ¥10,273 million (YoY -15.4%) / Operating profit ¥447 million (YoY -78.5%) / Ordinary income ¥791 million (YoY -67.0%) / Profit attributable to owners of parent for the quarter ¥344 million (YoY -78.5%) |
| Annual Dividend Forecast | ¥39 → ¥23（-41.0%） |
| Segment revenue | Pharmacy Systems Business ¥4,074 million (YoY -25.8%), Medical Systems Business ¥592 million (YoY -28.8%), Nursing Care and Welfare Systems Business ¥133 million (YoY +4.2%), Other Businesses ¥279 million (YoY -6.2%) |
| Segment profit | Pharmacy Systems Business ¥374 million (YoY -74.4%), Medical Systems Business ¥-170 million, Nursing Care and Welfare Systems Business ¥-76 million, Other Businesses ¥40 million (YoY +76.4%) |
| Depreciation and amortization | ¥205 million |
| Impairment loss | ¥97 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on sale of non-current assets / Amount Not disclosed / Extraordinary loss Item Loss on Disposal of Fixed Assets / Amount ¥4 million, Item Impairment Losses / Amount ¥97 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name 株式会社コンダクト / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 70,514,800 |
| Treasury Shares at Period-End | 1,293,795 |
| Factors Behind Changes in Business Performance | The concentrated demand for the introduction of online eligibility verification systems and electronic prescriptions had run its course, resulting in a reactionary decline. In order to expand the future earnings base, the Company shifted its sales strategy, curbed efforts to promote replacements for existing customers, and allocated more sales resources to acquiring new customers from other companies and selling value-added products. |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The concentrated demand for the introduction of online eligibility verification systems and electronic prescriptions had run its course, resulting in a reactionary decline, and the sales strategy was shifted from promoting replacements for existing customers to acquiring new customers from other companies and selling value-added products in order to expand the future earnings base.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.